Company Analysis
Sign in

Immunocore Holdings plc (IMCR)

Nasdaq: IMCR · Biological Products, (No Diagnostic Substances) · Oxfordshire, GB · filing with the SEC since 2016
Full chart Alerts Compare
Grade6.7
◀ Past 7.3● Present 6.6▶ Future 6.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedFeb 25, 2026Feb 26, 2025Feb 28, 2024Mar 1, 2023Mar 3, 2022Mar 25, 2021
Revenue400,016310,202249,428174,3614,078·
Cost of revenue5,0872,7311,0371,0890·
Research and development274,869222,151163,545101,921100,248·
Selling, general and administrative165,413155,781144,495123,059110,823·
Operating income-45,353-70,461-59,649-51,708-174,587·
Interest expense12,16618,8445,1545,4095,573·
Interest and investment income16,47625,61817,9863,75665·
Other income (expense), net19,72814,198-897-1,679-73·
Income before income taxes-19,100-52,937-60,890-40,883-179,879·
Income tax expense16,414-1,850-5,60311,660150·
Net income-35,514-51,087-55,287-52,543-180,029·
Earnings per share, basic-0.71-1.02-1.13-1.15-4.24·
Earnings per share, diluted-0.71-1.02-1.13-1.15-4.24·
Weighted average shares, basic50,345,66649,991,06448,888,97545,714,92342,488,579·
Weighted average shares, diluted50,345,66649,991,06448,888,97545,714,92342,488,579·
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:Revenues
Cost of revenue what it cost to make or buy what it soldus-gaap:CostOfRevenue
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpenseNonoperating
us-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton IMCR · research, not advice